Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Erdafitinib Intravesical Delivery System
Janssen Cilag International NV
Non-Muscle Invasive Bladder Neoplasms
1 trial -
Eribulin mesylate
HALOZYME THERAPEUTICS, INC.
Metastatic Breast Cancer
1 trial -
Erlotinib
United Therapeutics Europe Ltd
Non-Small Cell Lung Cancer
1 trial -
Erlotinib
Hoffmann-La Roche
Non-Small Cell Lung Cancer
1 trial -
Erlotinib
Hoffmann-La Roche
Pancreatic Cancer
1 trial -
Erlotinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small-cell Lung Cancer
1 trial -
Erlotinib
Solid Biosciences
Leptomeningeal Carcinomatosis
1 trial -
Erlotinib
United Therapeutics Europe Ltd
Lung Cancer
1 trial -
Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
Jazz Pharmaceuticals Ireland Limited
Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
1 trial -
Etigilimab
Mereo BioPharma Group plc
Solid Tumor, Adult
1 trial -
Etoposide
The First People's Hospital of Lianyungang
Small Cell Lung Cancer Limited Stage
1 trial -
Etrumadenant
Arcus Biosciences
Prostatic Neoplasms, Castration-Resistant
1 trial -
Etrumadenant (AB928)
Arcus Biosciences
Rectal Cancer
1 trial -
Everolimus
Takeda
Clear-cell Metastatic Renal Cell Carcinoma
1 trial -
Evorpacept (ALX148)
ALX ONCOLOGY HOLDINGS INC
Breast Cancer, Metastatic
1 trial -
Evorpacept (ALX148)
ALX ONCOLOGY HOLDINGS INC
Microsatellite Stable Metastatic Colorectal Cancer
1 trial -
Exercise Training
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Exicorilant
CORCEPT THERAPEUTICS INC
Metastatic Castration-Resistant Prostate Cancer
1 trial -
Expanded , Activated NK cells
Hospital Authority, Hong Kong
Ewing Sarcoma
1 trial -
Experimental
The First People's Hospital of Lianyungang
Locally Advanced Rectal Cancer (LARC)
1 trial -
Experimental: tislelizumab+anlotinib
The First People's Hospital of Lianyungang
Thymic Carcinoma
1 trial -
Extended-release Onapristone
Context Therapeutics
Refractory Endometrial Adenocarcinoma
1 trial -
F-FR-60000-023
Ipsen
Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors
1 trial -
F60087CI101
Pierre Fabre Medicament
locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)
1 trial -
FCN-437c+Fulvestrant
The First People's Hospital of Lianyungang
Breast Neoplasms
1 trial -
FDC fianlimab+cemiplimab
Regeneron UK Limited
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
FEMH-95011
Hospital Authority, Hong Kong
Stomach Neoplasms
1 trial -
FFCD 1605 OPTIPRIME
CERO THERAPEUTICS HOLDINGS, INC.
metastatic colorectal adenocarcinoma
1 trial -
FFCD 1709 - SIRTCI
CERO THERAPEUTICS HOLDINGS, INC.
microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis
1 trial -
FFCD 2006 NEORAF
CERO THERAPEUTICS HOLDINGS, INC.
BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER
1 trial -
FFCD1703
CERO THERAPEUTICS HOLDINGS, INC.
MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE
1 trial -
FGF401
Novartis Pharmaceuticals
Hepatocellular Carcinoma (HCC)
1 trial -
FHD-286
Foghorn Therapeutics
Small Cell Lung Cancer
1 trial -
FIL_COLUMN
Fondazione Telethon ETS
Mantle cell lymphoma
1 trial -
FIL_MOZART
Fondazione Telethon ETS
Follicular lymphoma
1 trial -
FIL_RI-CHOP
Fondazione Telethon ETS
Diffuse Large B-cell Lymphoma ABC
1 trial -
FIL_V-RBAC
Fondazione Telethon ETS
Mantle Cell Lymphoma
1 trial -
FOG-001
Parabilis Medicines
Cancer
1 trial -
FOLFIRI
Eisai Co.,
Colon Cancer
1 trial -
FOLFIRI regimen
Cardiff Oncology
Colorectal Cancer
1 trial -
FOLFIRNINOX
ACTUATE THERAPEUTICS, INC.
Pancreatic Adenocarcinoma
1 trial -
FOLFOX/FOLFIRI
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Unresectable or Metastatic Colorectal Cancer
1 trial -
FOLFOXIRI
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colon Cancer
1 trial -
FOLFOXIRI-based HAIC+Fuquinitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Neoplasms
1 trial -
FP-1039
Prime Medicine
Endometrial Cancers With FGFR2 Mutations
1 trial -
FRUZAQLA hard capsules for métastatique colorectal cancer
CERO THERAPEUTICS HOLDINGS, INC.
métastatique colorectal cancer
1 trial -
FRα peptide plus Adjuvant (GM-CSF)
Marker Therapeutics
Platinum Sensitive Ovarian Cancer
1 trial -
FULVESTRANT for advanced breast cancer
The George Institute
advanced breast cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.